Reply to Kaye and Belley, 'Third-Generation Cephalosporin-Resistant

Autor: Mark S, Butler, Valeria, Gigante, Hatim, Sati, Sarah, Paulin, Laila, Al-Sulaiman, John H, Rex, Prabhavathi, Fernandes, Cesar A, Arias, Mical, Paul, Guy E, Thwaites, Lloyd, Czaplewski, Richard A, Alm, Christian, Lienhardt, Melvin, Spigelman, Lynn L, Silver, Norio, Ohmagari, Roman, Kozlov, Stephan, Harbarth, Peter, Beyer

Publikováno v: Antimicrob Agents Chemother

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0b2db0b3fd1a34fe3ae36091dc172c77
https://pubmed.ncbi.nlm.nih.gov/35323013

Setting our sights on infectious diseases

Autor: Jen Southern, Maria Jose Lafuente-Monasterio, Pottage John C, Caitlin Taylor, William W. Hope, Srinivasa P. S. Rao, Didier Leroy, Jennifer Keiser, Sarah Cook, Clifton E. Barry, John P. Overington, Paul Herrling, Shyam Sundar, Olena Moshynets, David Horn, Lynn L. Silver, Valerie Mizrahi, Manu De Rycker, Isabela Ribeiro, Thomas Spangenberg, Ujjini H. Manjunatha, Nathalie Gobeau, Paul D. Leeson, Jacquin C. Niles, Nicholas J. White, Kevin D. Read, Susan Wyllie, Timothy J. Miles, Richard Amewu, Ian H. Gilbert, Frederick S. Buckner, Wesley C. Van Voorhis, James S. McCarthy, Paul G. Wyatt, Jennifer Herrmann, Michael A. J. Ferguson, Bree B. Aldridge

Publikováno v: ACS Infectious Diseases
ACS infectious diseases
ACS INFECTIOUS DISEASES

In May 2019, the Wellcome Centre for Anti-Infectives Research (; W; CAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4aded55419b192e43a1d93bef190a7b
https://eprints.gla.ac.uk/205951/1/205951.pdf

Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies

Autor: Cheryl L. Quinn, Jared A. Silverman, Jennifer A. Leeds, Lynn L. Silver, Laura McDowell

Publikováno v: SLAS discovery : advancing life sciences RD. 24(4)

For the past three decades, the pharmaceutical industry has undertaken many diverse approaches to discover novel antibiotics, with limited success. We have witnessed and personally experienced many mistakes, hurdles, and dead ends that have derailed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a5cd3ec20f88a84fe1e86021f49b479
https://pubmed.ncbi.nlm.nih.gov/30890054

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Autor: Angelo Pan, Sumanth Gandra, Elena Carrara, Souha S. Kanj, Karin Leder, Yang Soo Kim, Ana Cristina Gales, Christopher R. Houchens, Babacar Ndoye, Haibo Qiu, Lynn L. Silver, Jesús Rodríguez-Baño, Jasper Littman, David L. Paterson, Oliver J. Dyar, Paul Hansen, Mical Paul, Neil Woodford, Pilar Ramon-Pardo, Marie-Paule Kieny, Nalini Singh, Massinissa Si-Mehand, Wonkeung Song, Fidan O Yilmaz, Thomas Gottlieb, Jean B. Patel, Aaron O. Aboderin, Nguyen Van Kinh, Marc Mendelson, Seif Al-Abri, Manuel Guzman Blanco, Agnes Wechsler-Fördös, Waleria Hryniewicz, Vikas Manchanda, Timothy Jinks, Evelyn Wesangula, Gunnar Kahlmeter, Nicola Magrini, Otto Cars, Mike Sharland, Lawrence Kerr, Jaime Labarca, Debra A. Goff, Ursula Theuretzbacher, Francesco Robert Burkert, Gabriel Levy-Hara, Deepthi Kattula, Jan Kluytmans, Edward Cox, Jens Thomsen, Surbhi Malhotra-Kumar, Alexander W. Friedrich, Marco Cavaleri, Nordiah Awang Jalil, Maria Virginia Villegas, Roman S. Kozlov, Guy E. Thwaites, Kevin Outterson, Leonard Leibovici, Jos W. M. van der Meer, Stéphan Juergen Harbarth, Silvio Vega, Yehuda Carmeli, Dominique L Monnet, Lorenzo Moja, Heiman F. L. Wertheim, Martin Steinbakk, Giuseppe Cornaglia, Ramanan Laxminarayan, Maurizio Sanguinetti, Adrian Brink, Nur Benzonana, Sanjay Bhattacharya, Anna Zorzet, Alessia Savoldi, Céline Pulcini, Christian G. Giske, Herman Goossens, Evelina Tacconelli, M Lindsay Grayson, Sharmila Sengupta, Marc Ouellette

Publikováno v: Lancet Infectious Diseases, 18, 3, pp. 318-327
The Lancet Infectious Diseases
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2018, 18 (3), pp.318-327. ⟨10.1016/S1473-3099(17)30753-3⟩
The lancet infectious diseases
The Lancet Infectious Diseases, Vol. 18, No 3 (2018) pp. 318-327
Lancet Infectious Diseases, 18, 318-327

Summary Background The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18dd52a4205d1deff62e1257cc93dcfd
https://hdl.handle.net/2066/198275

Natural products as a source of drug leads to overcome drug resistance

Autor: Lynn L. Silver

Publikováno v: Future Microbiology. 10:1711-1718

Novel antibacterials may be found that can enhance the pipeline of therapeutics capable of overcoming antibiotic resistance by a return to exploration of natural products. Such novel products may be derived from both standard and previously uncultiva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2e43c6d2f059cacb0a7a66b33a7620
https://doi.org/10.2217/fmb.15.67